BioCentury | Dec 10, 2020
Deals

Late in a year of cancer deals, Gilead spends $1B+ to add an antiviral for HDV

...to acquire MYR GmbH, giving it a marketed antiviral that will complement its existing hepatitis franchise. MYR’s...
...biggest was its $21 billion purchase of Immunomedics Inc. in September, Gilead’s largest M&A deal ever.MYR’s...
...the company is based in Bad Homburg, Germany.TARGETSNTCP (SLC10A1) - Sodium taurocholate cotransporting polypeptide Paul Bonanos Gilead Sciences Inc. MYR GmbH bee2021 HDV...
BioCentury | Nov 1, 2019
Clinical News

Hepatitis D draft guidance outlines surrogate endpoints

...farnesyl transferase inhibitor from Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR), and Myrcludex bulevirtide, an NTCP inactivator from MYR GmbH...
...SLC10A1) - Sodium taurocholate cotransporting polypeptide Sandi Wong, Staff Writer Sarasar, lonafarnib (mk-6336, sch 066336) Myrcludex B FDA Eiger BioPharmaceuticals Inc. MYR GmbH...
BioCentury | Jul 11, 2019
Distillery Therapeutics

Adoptive transfer with T cells expressing anti-HBV TCRs for HBV

...combination with continuous infusion of Myrcludex B, an HBV entry inhibitor, eliminated detectable HBV-positive hepatocytes. MYR GmbH...
BioCentury | Apr 11, 2017
Clinical News

Myrcludex B: Completed Ph IIb MYR 203 enrollment

...Hepatera and MYR completed enrollment of 60 patients in the open-label, Russian Phase IIb MYR 203...
...pegylated interferon alpha-2a, and pegylated interferon alpha-2a alone for 48 weeks. Hepatera in-licensed rights from MYR...
...develop Myrcludex B in the Commonwealth of Independent States (CIS). Hepatera LLC , Moscow, Russia MYR GmbH...
BioCentury | Apr 10, 2017
Clinical News

Myrcludex B: Completed Ph IIb MYR 202 enrollment

...and MYR completed enrollment of 120 patients in the open-label, Russian and German Phase IIb MYR...
...trial to evaluate Myrcludex B with Viread tenofovir for 24 weeks. Hepatera in-licensed rights from MYR...
...develop Myrcludex B in the Commonwealth of Independent States (CIS). Hepatera LLC , Moscow, Russia MYR GmbH...
BioCentury | Jun 13, 2016
Clinical News

Myrcludex B: Phase IIb started

...The companies began the open-label, Russian Phase IIb MYR 203 trial to compare Myrcludex B plus...
...pegylated interferon alpha vs. pegylated interferon alpha alone in 60 patients. Hepatera in-licensed rights from MYR...
...develop Myrcludex B in the Commonwealth of Independent States (CIS). Hepatera LLC , Moscow, Russia MYR GmbH...
BioCentury | Apr 4, 2016
Clinical News

Myrcludex B: Phase IIb started

...The companies began the open-label, Russian and German Phase IIb MYR 202 trial to evaluate Myrcludex...
...to evaluate Myrcludex B with Viread tenofovir in about 120 patients. Hepatera in-licensed rights from MYR...
...develop Myrcludex B in the Commonwealth of Independent States (CIS). Hepatera LLC , Moscow, Russia MYR GmbH...
BioCentury | Apr 14, 2014
Clinical News

Myrcludex B: Pilot trial started

...Myrcludex from MYR to treat chronic HBV and HDV infections. Hepatera LLC , Moscow, Russia MYR GmbH...
BioCentury | Mar 17, 2014
Clinical News

Myrcludex B: Completed Phase IIa enrollment

...B daily for 12 weeks vs. Baraclude entecavir. Hepatera has rights to develop Myrcludex from MYR...
...infections. Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) markets Baraclude. Hepatera LLC , Moscow, Russia MYR GmbH...
BioCentury | Dec 17, 2012
Clinical News

Myrcludex B: Phase Ib/IIa started

...about 32 hepatitis B e antigen (HBeAg)-negative patients. Hepatera has rights to develop Myrcludex from MYR...
...D. Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) markets Baraclude. Hepatera LLC , Moscow, Russia MYR GmbH...
Items per page:
1 - 10 of 13
BioCentury | Dec 10, 2020
Deals

Late in a year of cancer deals, Gilead spends $1B+ to add an antiviral for HDV

...to acquire MYR GmbH, giving it a marketed antiviral that will complement its existing hepatitis franchise. MYR’s...
...biggest was its $21 billion purchase of Immunomedics Inc. in September, Gilead’s largest M&A deal ever.MYR’s...
...the company is based in Bad Homburg, Germany.TARGETSNTCP (SLC10A1) - Sodium taurocholate cotransporting polypeptide Paul Bonanos Gilead Sciences Inc. MYR GmbH bee2021 HDV...
BioCentury | Nov 1, 2019
Clinical News

Hepatitis D draft guidance outlines surrogate endpoints

...farnesyl transferase inhibitor from Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR), and Myrcludex bulevirtide, an NTCP inactivator from MYR GmbH...
...SLC10A1) - Sodium taurocholate cotransporting polypeptide Sandi Wong, Staff Writer Sarasar, lonafarnib (mk-6336, sch 066336) Myrcludex B FDA Eiger BioPharmaceuticals Inc. MYR GmbH...
BioCentury | Jul 11, 2019
Distillery Therapeutics

Adoptive transfer with T cells expressing anti-HBV TCRs for HBV

...combination with continuous infusion of Myrcludex B, an HBV entry inhibitor, eliminated detectable HBV-positive hepatocytes. MYR GmbH...
BioCentury | Apr 11, 2017
Clinical News

Myrcludex B: Completed Ph IIb MYR 203 enrollment

...Hepatera and MYR completed enrollment of 60 patients in the open-label, Russian Phase IIb MYR 203...
...pegylated interferon alpha-2a, and pegylated interferon alpha-2a alone for 48 weeks. Hepatera in-licensed rights from MYR...
...develop Myrcludex B in the Commonwealth of Independent States (CIS). Hepatera LLC , Moscow, Russia MYR GmbH...
BioCentury | Apr 10, 2017
Clinical News

Myrcludex B: Completed Ph IIb MYR 202 enrollment

...and MYR completed enrollment of 120 patients in the open-label, Russian and German Phase IIb MYR...
...trial to evaluate Myrcludex B with Viread tenofovir for 24 weeks. Hepatera in-licensed rights from MYR...
...develop Myrcludex B in the Commonwealth of Independent States (CIS). Hepatera LLC , Moscow, Russia MYR GmbH...
BioCentury | Jun 13, 2016
Clinical News

Myrcludex B: Phase IIb started

...The companies began the open-label, Russian Phase IIb MYR 203 trial to compare Myrcludex B plus...
...pegylated interferon alpha vs. pegylated interferon alpha alone in 60 patients. Hepatera in-licensed rights from MYR...
...develop Myrcludex B in the Commonwealth of Independent States (CIS). Hepatera LLC , Moscow, Russia MYR GmbH...
BioCentury | Apr 4, 2016
Clinical News

Myrcludex B: Phase IIb started

...The companies began the open-label, Russian and German Phase IIb MYR 202 trial to evaluate Myrcludex...
...to evaluate Myrcludex B with Viread tenofovir in about 120 patients. Hepatera in-licensed rights from MYR...
...develop Myrcludex B in the Commonwealth of Independent States (CIS). Hepatera LLC , Moscow, Russia MYR GmbH...
BioCentury | Apr 14, 2014
Clinical News

Myrcludex B: Pilot trial started

...Myrcludex from MYR to treat chronic HBV and HDV infections. Hepatera LLC , Moscow, Russia MYR GmbH...
BioCentury | Mar 17, 2014
Clinical News

Myrcludex B: Completed Phase IIa enrollment

...B daily for 12 weeks vs. Baraclude entecavir. Hepatera has rights to develop Myrcludex from MYR...
...infections. Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) markets Baraclude. Hepatera LLC , Moscow, Russia MYR GmbH...
BioCentury | Dec 17, 2012
Clinical News

Myrcludex B: Phase Ib/IIa started

...about 32 hepatitis B e antigen (HBeAg)-negative patients. Hepatera has rights to develop Myrcludex from MYR...
...D. Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) markets Baraclude. Hepatera LLC , Moscow, Russia MYR GmbH...
Items per page:
1 - 10 of 13